PL217410B1
(pl)
*
|
2000-05-19 |
2014-07-31 |
Genentech Inc |
Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
AU2004217434B2
(en)
*
|
2000-12-08 |
2010-08-26 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
*
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
EP1341902A2
(en)
*
|
2000-12-08 |
2003-09-10 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US7452539B2
(en)
*
|
2001-12-19 |
2008-11-18 |
Genentech, Inc. |
Stabilizing polypeptides which have been exposed to urea
|
CA2472186A1
(en)
*
|
2002-01-18 |
2003-07-31 |
Chiron Corporation |
Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein
|
EP1531850B1
(en)
*
|
2002-06-07 |
2012-02-22 |
ZymoGenetics, Inc. |
Use of IL-21 and monoclonal antibody for treating solid cancers
|
ATE537842T1
(de)
|
2002-07-01 |
2012-01-15 |
Wilex Ag |
Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
|
US20050265966A1
(en)
*
|
2004-05-20 |
2005-12-01 |
Kindsvogel Wayne R |
Methods of treating cancer using IL-21 and monoclonal antibody therapy
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
AU2006210572B2
(en)
|
2005-02-03 |
2011-08-04 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
SI1850874T1
(sl)
|
2005-02-23 |
2014-01-31 |
Genentech, Inc. |
Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
US8105768B2
(en)
|
2005-03-09 |
2012-01-31 |
Abbott Laboratories |
Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
US20070111906A1
(en)
*
|
2005-11-12 |
2007-05-17 |
Milner Jeffrey L |
Relatively low viscosity transmission fluids
|
SG10201400426XA
(en)
|
2006-01-12 |
2014-07-30 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
DE102006011507A1
(de)
*
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
EP2054444B1
(en)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antibodies to erbb2
|
AU2008223069B2
(en)
|
2007-03-02 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
Predicting response to a HER dimerisation inhibitor based on low HER3 expression
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
EP2171090B1
(en)
*
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
EP2185593B1
(en)
*
|
2007-07-25 |
2017-12-13 |
Alexion Pharmaceuticals, Inc. |
Compositions for treating autoimmune disease
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
CA2725598C
(en)
|
2008-06-17 |
2013-10-08 |
Wyeth Llc |
Antineoplastic combinations containing hki-272 and vinorelbine
|
WO2010017163A1
(en)
|
2008-08-04 |
2010-02-11 |
Wyeth |
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
|
EP2362783A2
(en)
|
2008-10-31 |
2011-09-07 |
Biogen Idec MA Inc. |
Light targeting molecules and uses thereof
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
KR20140036332A
(ko)
|
2009-04-06 |
2014-03-25 |
와이어쓰 엘엘씨 |
네라티닙을 이용한 유방암의 치료법
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
CA2786692A1
(en)
|
2010-01-11 |
2011-07-14 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
EP2534178A4
(en)
|
2010-02-11 |
2013-08-07 |
Alexion Pharma Inc |
THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
CN103890007A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
神经调节蛋白抗体及其用途
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
SG11201402510TA
(en)
|
2011-11-30 |
2014-06-27 |
Genentech Inc |
Erbb3 mutations in cancer
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
AU2015229583B2
(en)
|
2014-03-11 |
2020-07-09 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
EP3825327A1
(en)
|
2014-03-11 |
2021-05-26 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
RU2016144176A
(ru)
|
2014-04-11 |
2018-05-14 |
МЕДИММЬЮН, ЭлЭлСи |
Биспецифические антитела к her2
|
US9586056B2
(en)
|
2014-07-03 |
2017-03-07 |
Haniva Llc |
Combination therapy for treating cancer and method for treating cancer using a combination therapy
|
WO2016052971A1
(ko)
*
|
2014-09-30 |
2016-04-07 |
가톨릭대학교 산학협력단 |
유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법
|
EP3660035A1
(en)
|
2015-05-30 |
2020-06-03 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
CA2991259A1
(en)
|
2015-07-26 |
2017-02-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
US20200024312A1
(en)
|
2017-01-25 |
2020-01-23 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
WO2018217989A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
MX2019009726A
(es)
|
2018-04-17 |
2020-02-05 |
Molecular Templates Inc |
Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
|
JP2022533702A
(ja)
|
2019-05-20 |
2022-07-25 |
パンディオン・オペレーションズ・インコーポレイテッド |
MAdCAM標的化免疫寛容
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|